Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on US Healthcare Journal.
Press releases published on May 9, 2025
Vystar Develops Revolutionary Leap in Air Purification Utilizing its Patented Hughes Reactor
GlobeNewswire
·
May 9, 2025
Boston, MA, May 09, 2025 (GLOBE NEWSWIRE) -- Vystar® Corporation (OTCQB: VYST) Vystar has completed what it believes to be a revolutionary, next-generation RXAIR prototype using the new Fluid Energy Conversion - Hughes Reactor. The Hughes Reactor was …
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
GlobeNewswire
·
May 9, 2025
SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced an exclusive license and commercialization agreement for Lotus to …
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
GlobeNewswire
·
May 9, 2025
MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the …
Outset Medical to Present at RBC Global Healthcare Conference
GlobeNewswire
·
May 9, 2025
SAN JOSE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of …
NEXGEL to Report First Quarter 2025 Financial Results on May 13th
GlobeNewswire
·
May 9, 2025
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for …
SRx Health Solutions Purchases $1.5 Million of Solana Tokens as Part of its Asset Allocation Diversification Strategy
GlobeNewswire
·
May 9, 2025
TAMPA, Fla., May 09, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”), a leading global health and wellness company, today announced purchasing Solana Tokens (SOL) for approximately $1.5 million as part of the …
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
GlobeNewswire
·
May 9, 2025
Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. …
Renowned Neurosurgeon Dr. Mohana Rao (Dr. Rao) Chooses Guntur Over Global Metropolises, Revolutionizing Local Healthcare
EIN Presswire
·
May 9, 2025
Dr. Mohana Rao Patibandla's Quiet Revolution in Neurosurgery GUNTUR, ANDHRA PRADESH, INDIA, May 9, 2025 /EINPresswire.com/ -- Renowned Neurosurgeon Dr. Rao Chooses Guntur Over Global Metropolises, Revolutionizing Local Healthcare Dr. Mohana Rao …
Garuda Therapeutics Announces Name Change to Stratus Therapeutics to Reflect Mission of Pioneering Full Hematopoietic System Renewal
GlobeNewswire
·
May 9, 2025
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Garuda Therapeutics (“Garuda”), a biotechnology company developing off-the-shelf hematopoietic stem cell (HSC) therapies, today announced that it has changed its name to Stratus Therapeutics, Inc. (“ …
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights
GlobeNewswire
·
May 9, 2025
Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Interim analysis from Phase 2 PYNNACLE trial expected mid-2025; PMV plans to …
BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President
GlobeNewswire
·
May 9, 2025
SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today …
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
GlobeNewswire
·
May 9, 2025
- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson’s disease - RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy …
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
GlobeNewswire
·
May 9, 2025
PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in Vision …
Anika Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 9, 2025
First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating …
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
GlobeNewswire
·
May 9, 2025
IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master …
Rapid Micro Biosystems Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 9, 2025
Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly service revenue led by strong validation activity. Reports first quarter gross margin of 6%, representing a 33 …
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
GlobeNewswire
·
May 9, 2025
WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris’ Chief …
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
GlobeNewswire
·
May 9, 2025
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the …
Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
May 9, 2025
Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for mid-2025 development candidate nomination and IND filing …
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
GlobeNewswire
·
May 9, 2025
FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the first independent validation of the recently …